...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Infectious Diseases and Therapy >Two’s a Company, Three’s a Crowd: A Review of Initiating or Switching to a Two-Drug Antiretroviral Regimen in Treatment-Na?ve and Treatment-Experienced Patients Living with HIV-1
【24h】

Two’s a Company, Three’s a Crowd: A Review of Initiating or Switching to a Two-Drug Antiretroviral Regimen in Treatment-Na?ve and Treatment-Experienced Patients Living with HIV-1

机译：两家公司，三个人群：审查启动或转向治疗治疗和治疗经验丰富的患有HIV-1的患者的两种药物抗逆转录病毒方案

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

IntroductionAs HIV has become a manageable chronic condition, a renewed and increased interest in challenging traditional three-drug HIV therapies and moving toward two-drug regimens (2DR) for initial or maintenance treatment in people living with HIV (PLWH) has developed. As PLWH are living longer, continual advancements in antiretroviral regimens have been a focus to provide optimal life-long therapy options. Although early studies may have shown poor outcomes in virologic suppression with 2DR, newer studies and treatment options have emerged to show promise in the management of HIV. The purpose of this review is to evaluate current literature and assess the efficacy of two-drug (2DR) antiretroviral therapy in treatment-na?ve and -experienced people living with HIV.MethodsA systematic search was performed between January 2009 to January 2020, using EMBASE, MEDLINE, Google Scholar, and bibliographies. Combinations of the following search terms were used: HIV-1 infection, antiretroviral therapy, dual therapy, two-drug regimen, two-drug therapy, two-drug regimen, and 2DR. Included studies were those in the adult population with at least one active comparator, outcomes assessing HIV-1 RNA viral load while on treatment, and written in English.ResultsThirty-three studies were included, 13 where 2DRs were evaluated as initial therapy (3 studies with extension data) and 15 where 2DRs were evaluated as maintenance or switch therapy (2 studies with extension data).ConclusionAlthough 2DRs may not be appropriate in all patient populations, they are being utilized more frequently and have the potential to reduce costs, adverse effects, and drug interactions.
机译：简介艾滋病毒已成为一个可管理的慢性病条件，对挑战传统三种药物HIV疗法的更新和增加的兴趣，并朝着与艾滋病毒（PLWH）的人们的初始或维持治疗进行了初始或维持治疗的初始或维持治疗。由于PLWH生活更长时间，抗逆转录病毒方案的持续进步是提供最佳的终身疗法选择。虽然早期研究可能在病毒学抑制中表现出较差的病毒学抑制，但新的研究和治疗方案已经出现了在艾滋病毒的管理中表现出承诺。本综述的目的是评估当前的文献，并评估两种药物（2DR）抗逆转录病毒治疗治疗治疗的疗效 - Na've，患有HIV.Methodsa的培养人员在2009年1月至2020年之间进行了系统搜索，使用Embase，Medline，Google学者和书目。使用以下搜查术语的组合：HIV-1感染，抗逆转录病毒治疗，双重治疗，双药方案，双药治疗，双药方程纲和2DR。包括的研究是成年人群中的至少一个活性比较剂，结果评估HIV-1 RNA病毒载荷，同时治疗，并用英文书写。包括含有33项研究，其中2DRS被评估为初始治疗（3项研究延长数据）和15其中2DR被评估为维护或切换治疗（2个延长数据的研究）。虽然2DR在所有患者群体中可能不合适，但它们正在更频繁地利用并且有可能降低成本，不利影响和药物相互作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号